Accretion Therapeutics
Lincolnshire, US · Founded 2026 · Delaware corporation
Find your way into Accretion Therapeutics
Sign up to see every warm intro you have to Accretion Therapeutics
- Paths you didn't know you had: your email and LinkedIn already hold routes to the Accretion Therapeutics team. We find them for you
- 2nd- and 3rd-degree connections: the friend-of-a-friend routes that take hours to manually find through your inbox or LinkedIn
- Answers now, not in days: momentum is everything in a raise. Skip asking around whether someone knows someone
Days of research, done the moment you sign in, with every route ranked by how warm it is.
Founders & leadership
DH
David HolecekExecutive
Reported raises · per SEC filings
Form D private placements$750K disclosed across 1 round · 2026
▶$750KraisedFeb 2026 · 1 investors · PharmaceuticalsRule 506(b)
▶$750KraisedFeb 2026 · 1 investors · Pharmaceuticals
Rule 506(b)Officers, directors & promoters on the filing
- David HolecekExecutive Officer, Director
- Offering amount
- $1M
- Amount sold
- $750K
- Minimum investment
- $750K
- First sale
- Feb 2026
- Incorporated
- Corporation, Delaware, 2026
- Federal exemptions
- 06b
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.
Frequently asked questions
- How much funding has Accretion Therapeutics raised?
- Accretion Therapeutics has disclosed $750K raised across 1 round.
- Where is Accretion Therapeutics headquartered?
- Accretion Therapeutics is headquartered in Lincolnshire, US.